| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| U0004 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r |
1,185 |
1,052 |
$148K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
807 |
675 |
$58K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
861 |
731 |
$47K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
1,543 |
1,325 |
$43K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
199 |
184 |
$28K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
83 |
76 |
$19K |
| 87428 |
|
92 |
84 |
$5K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
132 |
120 |
$4K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
16 |
15 |
$2K |
| 0012A |
|
18 |
18 |
$665.04 |
| 0011A |
|
19 |
19 |
$646.15 |